Tid Tittel Kategori Vedlegg
25.09.2026
23:35
 Nykode Therapeutics receives ruling from Tax Appeal Board in pending tax case INFORMASJON INF
1
09.09.2026
14:59
 Nykode Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference -
1
31.08.2026
15:26
 Nykode Therapeutics ASA - New share capital registered - -
31.08.2026
11:35
 Mandatory notification of transaction INSIDEHANDEL INS
1
28.08.2026
00:20
 Mandatory notification of trade INSIDEHANDEL INS
1
27.08.2026
23:51
 Nykode Therapeutics ASA - Private Placement Completed INFORMASJON INF -
27.08.2026
16:32
 Nykode Therapeutics ASA - Contemplated Private Placement INFORMASJON INF -
26.08.2026
15:15
 Nykode Therapeutics receives draft recommendation from Secretariat of Tax Appeal Board in pending tax case INFORMASJON INF
1
26.08.2026
07:00
 Nykode Therapeutics - Quarterly Report Q2 2026 RAPPORT RAP
1
21.08.2026
19:19
 Nykode Therapeutics – Invitation to Q2 2026 Financial Results Presentation -
1
20.08.2026
15:22
 Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program -
1
06.08.2026
20:05
 Nykode Therapeutics - Grant of share options INSIDEHANDEL INS
1
04.08.2026
22:15
 Nykode Therapeutics - update on expected timeline for pending tax appeal - -
22.07.2026
14:00
 Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO -
1
27.05.2026
07:00
 Nykode Therapeutics - Quarterly Report Q1 2026 RAPPORT RAP
1
18.05.2026
11:34
 Nykode Therapeutics – Invitation to Q1 2026 Financial Results Presentation -
1
13.05.2026
11:15
 Nykode Therapeutics ASA - Minutes of Annual General Meeting -
1
07.05.2026
13:54
 Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients -
1
30.04.2026
08:30
 Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026 -
1
21.04.2026
08:30
 Nykode Therapeutics ASA - Notice of Annual General Meeting -
1
20.04.2026
12:00
 Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting -
1
17.04.2026
07:30
 Nykode Therapeutics - Annual Report 2025 RAPPORT RAP
2
20.03.2026
14:45
 Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026 -
1
18.03.2026
08:30
 Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026 -
1
09.03.2026
08:30
 Nykode Therapeutics to Present at DNB Carnegie Conference on March 10, 2026 -
1